Browsing Tag
Sentynl Therapeutics
3 posts
Zydus Lifesciences stock edges higher as Sentynl faces FDA CRL for CUTX-101
Zydus Lifesciences’ U.S. unit Sentynl received an FDA Complete Response Letter for CUTX-101. Find out why investors remain optimistic despite regulatory delays.
Sentynl Therapeutics acquires Eiger BioPharmaceuticals’ Zokinvy program to expand portfolio in rare diseases
Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd. (Zydus Group), has closed the…
Zydus Group’s Sentynl Therapeutics gains full control of Menkes Disease candidate CUTX-101
Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company under Zydus Lifesciences, Ltd., has finalized an agreement with Cyprium Therapeutics,…